The rationale for using low-molecular weight heparin in the therapy of symptomatic COVID-19 patients
Accumulated evidence suggest that the adverse outcome of severe coronavirus disease 2019 (COVID-19) is closely related to prothrombotic microvascular pathology with a high risk of venous thromboembolism. Furthermore, the first observational studies indicated that adjunct therapy with low-molecular w...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2022-01-01
|
Series: | Open Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1515/med-2021-0374 |